Novartis Sues Generics Maker Over Organ Rejection Drug
By Joe Van Acker (September 16, 2014, 2:24 PM EDT) -- Novartis Pharmaceuticals Corp. hit Roxane Laboratories Inc. with a patent infringement suit in Delaware federal court Tuesday in an effort to block a generic version of Zortress, a medication used to treat organ transplant recipients.
Novartis told the court Roxane violated four of its patents when it filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to manufacture tablets containing everolimus, the active ingredient in Zortress. In a Tuesday statement, Novartis said it is prepared to strongly defend its patents.
"Novartis Pharmaceuticals Corp. strongly believes in appropriately defending the intellectual property rights and patents of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!